Evidence mapPaperPMID 42514979Full record

ReviewPharmaceutics2026

Advances in Intranasal CNS Targeting: Integrating Formulations, Devices, Computational Fluid Dynamics, and 3D Printing.

Lena Shaghlil, Yousef Al-Ebini, Mahmoud J Al Shawabkeh, Fatmawati Adam, Kuldeep K Saxena, Anas Alshishani, Wan Sharuzi Wan Harun

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lena ShaghlilFaculty of Mechanical and Automotive Engineering Technology, Universiti Malaysia Pahang Al-Sultan Abdullah, Pekan 26600, Pahang, Malaysia.ORCID 0000-0003-0240-6816
Yousef Al-EbiniDepartment of Cosmetic Science, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman 19328, Jordan.ORCID 0000-0002-1198-651X
Mahmoud J Al ShawabkehDepartment of Oral Surgery and Diagnostic Sciences, Applied Science Private University, Amman 11937, Jordan.
Fatmawati AdamCenter for Research in Advanced Fluid & Processes, Universiti Malaysia Pahang Al-Sultan Abdullah, Kuantan 26300, Pahang, Malaysia.
Kuldeep K SaxenaDepartment of Mechanical Engineering, Bennett University, Greater Noida 201310, India.ORCID 0000-0003-4064-5113
Anas AlshishaniResearch and Development Department, PharmaPrimes Lab, Amman 11190, Jordan.ORCID 0000-0002-0040-5492
Wan Sharuzi Wan HarunFaculty of Mechanical and Automotive Engineering Technology, Universiti Malaysia Pahang Al-Sultan Abdullah, Pekan 26600, Pahang, Malaysia.ORCID 0000-0002-1673-5584

Funding

Fundamental Research Grant Scheme FRGS/1/2024/TK09/UMP/02/6
6 · The paper itself

Abstract

Nose-to-brain (N2B) delivery is a practical, non-invasive strategy for CNS targeting that can increase brain exposure while limiting systemic exposure. This review integrates three milestones in N2B delivery, formulations, devices, and quantitative evaluation strategies, to define design rules for effective olfactory/trigeminal deposition and enhance translational relevance. Formulations emphasize mucoadhesive systems, nanoparticle carriers (polymeric, lipid-based, and hybrid), nano-emulsions, and stimuli-responsive "smart" gels that prolong nasal residence. Regarding device advancements, the review covers conventional nasal sprays optimized for plume geometry and droplet size. Furthermore, it examines breath-actuated metered sprays, which promote soft palate closure to route aerosols to superior regions, and vibrating mesh nebulizers capable of low-velocity mists for improved upper cavity deposition. Quantitative evaluation is discussed, including 3D-printed, anatomy-accurate nasal casts, high-speed spray diagnostics, and computational fluid dynamics (CFD). This review further links formulation and device parameters to regional deposition. Available clinical and animal data illustrate the feasibility of these approaches, safety considerations, and user-technique dependencies, while highlighting the need for standardized, anatomy-aware testing protocols. Together, these developments suggest that co-designed formulation device platforms, validated by cast/CFD metrics and supported by clinical imaging or pharmacokinetic data, can support N2B product development toward consistent, patient-relevant outcomes.

Indexed as

3D nasal castsmucoadhesive systemsnanoparticle carriersnasal devicesnasal spraynose-to-brainsmart polymers

Identifiers

PMID42514979
PMCPMC13414907

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.